Literature DB >> 12719547

Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.

David E Ott1, Lori V Coren, Elena N Chertova, Tracy D Gagliardi, Kunio Nagashima, Raymond C Sowder, Dexter T K Poon, Robert J Gorelick.   

Abstract

The nucleocapsid (NC) region of human immunodeficiency virus type 1 (HIV-1) Gag is required for specific genomic RNA packaging. To determine if NC is absolutely required for virion formation, we deleted all but seven amino acids from NC in a full-length NL4-3 proviral clone. This construct, DelNC, produced approximately four- to sixfold fewer virions than did the wild type, and these virions were noninfectious (less than 10(-6) relative to the wild type) and severely genomic RNA deficient. Immunoblot and high-pressure liquid chromatography analyses showed that all of the mature Gag proteins except NC were present in the mutant virion preparations, although there was a modest decrease in Gag processing. DelNC virions had lower densities and were more heterogeneous than wild-type particles, consistent with a defect in the interaction assembly or I domain. Electron microscopy showed that the DelNC virions displayed a variety of aberrant morphological forms. Inactivating the protease activity of DelNC by mutation or protease inhibitor treatment restored virion production to wild-type levels. DelNC-protease mutants formed immature-appearing particles that were as dense as wild-type virions without incorporating genomic RNA. Therefore, protease activity combined with the absence of NC causes the defect in DelNC virion production, suggesting that premature processing of Gag during assembly causes this effect. These results show that HIV-1 can form particles efficiently without NC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719547      PMCID: PMC154014          DOI: 10.1128/jvi.77.10.5547-5556.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.

Authors:  S J Arrigo; K Huffman
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

2.  An assembly domain of the Rous sarcoma virus Gag protein required late in budding.

Authors:  J W Wills; C E Cameron; C B Wilson; Y Xiang; R P Bennett; J Leis
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

3.  The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.

Authors:  A H Kaplan; M Manchester; R Swanstrom
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Specificity and sequence requirements for interactions between various retroviral Gag proteins.

Authors:  E K Franke; H E Yuan; K L Bossolt; S P Goff; J Luban
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.

Authors:  V Karacostas; E J Wolffe; K Nagashima; M A Gonda; B Moss
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

6.  Site-directed mutagenesis of the P2 region of the Rous sarcoma virus gag gene: effects on Gag polyprotein processing.

Authors:  N Bowles; D Bonnet; F Mulhauser; P F Spahr
Journal:  Virology       Date:  1994-08-15       Impact factor: 3.616

7.  Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.

Authors:  A H Kaplan; P Krogstad; D J Kempf; D W Norbeck; R Swanstrom
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity.

Authors:  B G Luukkonen; E M Fenyö; S Schwartz
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

9.  Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins.

Authors:  R P Bennett; T D Nelle; J W Wills
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles.

Authors:  C Carrière; B Gay; N Chazal; N Morin; P Boulanger
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  35 in total

1.  Role of the C terminus of foamy virus Gag in RNA packaging and Pol expression.

Authors:  Carolyn R Stenbak; Maxine L Linial
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Basic residues of the retroviral nucleocapsid play different roles in gag-gag and Gag-Psi RNA interactions.

Authors:  Eun-Gyung Lee; Maxine L Linial
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

3.  Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding.

Authors:  Vincent Dussupt; Paola Sette; Nana F Bello; Melodi P Javid; Kunio Nagashima; Fadila Bouamr
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

4.  Ty3 nucleocapsid controls localization of particle assembly.

Authors:  Liza S Z Larsen; Nadejda Beliakova-Bethell; Virginia Bilanchone; Min Zhang; Anne Lamsa; Rhonda Dasilva; G Wesley Hatfield; Kunio Nagashima; Suzanne Sandmeyer
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 5.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

6.  Quantitative fluorescence resonance energy transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-Gag interaction: relative contributions of the CA and NC domains and membrane binding.

Authors:  Ian B Hogue; Adam Hoppe; Akira Ono
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

Review 7.  Diverse interactions of retroviral Gag proteins with RNAs.

Authors:  Alan Rein; Siddhartha A K Datta; Christopher P Jones; Karin Musier-Forsyth
Journal:  Trends Biochem Sci       Date:  2011-05-06       Impact factor: 13.807

8.  Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain.

Authors:  Vineela Chukkapalli; Seung J Oh; Akira Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

9.  Cryo electron tomography of native HIV-1 budding sites.

Authors:  Lars-Anders Carlson; Alex de Marco; Heike Oberwinkler; Anja Habermann; John A G Briggs; Hans-Georg Kräusslich; Kay Grünewald
Journal:  PLoS Pathog       Date:  2010-11-24       Impact factor: 6.823

10.  The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding.

Authors:  Vincent Dussupt; Melodi P Javid; Georges Abou-Jaoudé; Joshua A Jadwin; Jason de La Cruz; Kunio Nagashima; Fadila Bouamr
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.